Want to see GB:APTA full AI Analyst Report?
APTA Stock Chart & Stats
0.48 p
-0.03 p(-5.26%)
At close: 4:00 PM EDT
0.48 p
-0.03 p(-5.26%)
Day’s Range― - ―
52-Week Range0.40 p - 1.57 p
Previous CloseN/A
Volume1.65M
Average Volume (3M)15.29M
Market Cap
£16.41M
Enterprise Value13.44M
Total Cash (Recent Filing)£1.53M
Total Debt (Recent Filing)£333.00K
Price to Earnings (P/E)―
Beta0.43
Next Earnings
Oct 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,455,144,000
10 Day Avg. Volume14,821,052
30 Day Avg. Volume15,285,032
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)5.32
Price to Sales (P/S)6.11
P/FCF Ratio-3.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Aptamer Platform & ServicesAptamer Group's core technology and service offering is a platform-level capability: aptamer discovery and development for diagnostics, research and therapeutic applications. Platform strength supports recurring collaborations, licensing and integration into partner products, creating durable revenue channels if commercial traction improves.
Improved Balance Sheet LeverageAn improved debt-to-equity ratio increases financial flexibility and reduces near-term refinancing risk. For a small biotech still investing in R&D, lower leverage helps extend runway and gives management more options to fund commercialization or partnerships without immediate dilutive financing.
Lean Specialized TeamA small, focused headcount lowers fixed overhead and enables nimble allocation of R&D resources. For a platform and services model, this allows scaling via partner collaborations rather than heavy internal expansion, preserving cash while pursuing targeted commercial opportunities and iterative product development.
Bears Say
Severe Revenue CollapseA near-total revenue collapse is a fundamental red flag for sustainable operations and market traction. Such a drop undermines ability to retain customers, validate the platform commercially, and justify R&D spend, making it difficult to rebuild recurring revenues without material strategic shifts or new partnerships.
Negative Operating And Free Cash FlowConsistent negative operating and free cash flows indicate the business is burning cash to operate and grow. Over months this erodes liquidity, forces management to prioritize short-term survival over product investment, and typically necessitates external financing that can dilute shareholders or increase leverage.
Persistent Losses And Negative ROEOngoing losses and negative ROE show the company is not generating returns on invested capital. This limits reinvestment ability, weakens negotiating leverage with partners, and raises the risk that additional capital will be required before the platform achieves profitable scale, pressuring long-term viability.
Aptamer Group Plc News
APTA FAQ
What was Aptamer Group Plc’s price range in the past 12 months?
Aptamer Group Plc lowest share price was 0.40 p and its highest was 1.57 p in the past 12 months.
What is Aptamer Group Plc’s market cap?
Aptamer Group Plc’s market cap is £16.41M.
When is Aptamer Group Plc’s upcoming earnings report date?
Aptamer Group Plc’s upcoming earnings report date is Oct 20, 2026 which is in 75 days.
How were Aptamer Group Plc’s earnings last quarter?
Aptamer Group Plc released its earnings results on Mar 25, 2026. The company reported 0 p earnings per share for the quarter, the consensus estimate of N/A by 0 p.
Is Aptamer Group Plc overvalued?
According to Wall Street analysts Aptamer Group Plc’s price is currently Overvalued.
Does Aptamer Group Plc pay dividends?
Aptamer Group Plc does not currently pay dividends.
What is Aptamer Group Plc’s EPS estimate?
Aptamer Group Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aptamer Group Plc have?
Aptamer Group Plc has 3,455,144,000 shares outstanding.
What happened to Aptamer Group Plc’s price movement after its last earnings report?
Aptamer Group Plc reported an EPS of 0 p in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -3.846%.
Which hedge fund is a major shareholder of Aptamer Group Plc?
Currently, no hedge funds are holding shares in GB:APTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aptamer Group Plc
Aptamer Group plc, an international company headquartered in York, United Kingdom, specializes in providing advanced binders for applications spanning research, diagnostics, and therapeutics. Their innovative binder technology is engineered to resolve challenges often associated with traditional molecular tools, such as antibodies, offering crucial solutions to bioprocessing, diagnostic, and pharmaceutical scientists. Established in 2014, the company primarily serves pharmaceutical corporations, diagnostic development firms, and various research institutes.
Technical Analysis
Avacta Group plc
―
Bioventix
―
Oxford BioDynamics
―
Fusion Antibodies Plc
―
Arecor Therapeutics PLC
―